🧬 BioMed Pulse · 2026-11-10 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Tuesday, November 10, 2026 | 02:00 UTC

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has now spread to Kenya and Nigeria and continues to intensify, making it the largest Ebola-family outbreak ever recorded in the DRC, with no sign of containment. Meanwhile a first-ever human case of Shamonda virus was confirmed in France just days ago, adding a novel neurological pathogen to an already crowded threat landscape — the overall mood is elevated concern.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (DRC, KENYA, NIGERIA) - THE BIG ONE

  • As of the November 6, 2026 WHO Disease Outbreak News, the Bundibugyo virus (BVD) outbreak in the DRC has expanded geographically since the October 23 update, with Kenya and Nigeria now reporting imported cases alongside sustained high-level transmission in the DRC. [1]
  • WHO's October 23 DON noted the outbreak had already reached multiple DRC provinces; since October 8, an imported case in Kenya with DRC travel history was confirmed and that patient was hospitalized. [2] [3]
  • As of August 14 WHO reporting, the outbreak was described as the largest Ebola outbreak ever reported in the DRC, expanding faster than any previous Ebola outbreak, with more than 60 health zones ultimately affected across six provinces including Ituri, North Kivu, South Kivu, Haut-Uele, Bas-Uele, and Tshopo. [4] [5]
  • The case fatality burden as of the July 17 WHO update stood at 828 deaths among 2,124 confirmed cases; subsequent updates tracked continued acceleration through August and September. [6]
  • CDC had mobilized Ebola response as of May 17, 2026, expanded airport screening to Washington-Dulles International Airport and later to Atlanta's Hartsfield-Jackson. [7] [8] [9]

SHAMONDA VIRUS - FIRST HUMAN CASE, FRANCE

  • On November 2, 2026, WHO published a Disease Outbreak News on the first documented human infection with Shamonda virus (SHAV), a rare bunyavirus, in an immunocompromised older man from eastern France with no travel history in the preceding year. [10]
  • The patient developed severe neurological symptoms; France's National IHR Focal Point notified WHO on October 20, 2026, making this a globally novel event requiring close monitoring for further cases. [10]

YELLOW FEVER - AFRICA AND AMERICAS

  • WHO's November 6, 2026 DON reported that between January 1 and October 12, 2026, nine countries in the WHO African Region recorded 67 confirmed yellow fever cases including 18 deaths, with outbreak activity concentrated in West Africa including Burkina Faso and Cameroon.
  • A June 24 WHO DON had also flagged ongoing yellow fever transmission in six countries in the Americas from January through May 26, 2026, with 79 human infections, as spillover from elevated 2025 activity continued into 2026.

MERS-CoV - SAUDI ARABIA

  • Between January 1 and October 5, 2026, the Kingdom of Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases including one death, with infections detected across six locations including Riyadh, Tabuk, and Al Jouf, per a WHO Disease Outbreak News dated October 15, 2026.

PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA

  • On October 10, 2026, WHO published a DON noting it had become aware of the death of an employee of the Irkutsk Antiplague Research Institute of Siberia in the Russian Federation, who died on October 2 following hospitalization for severe pneumonia; the etiology remains undetermined and WHO is monitoring.

NIPAH VIRUS - INDIA

  • A June 25, 2026 WHO DON confirmed a single laboratory-confirmed Nipah virus (NiV) case in Kozhikode district, Kerala State, India, in an adult male with neurological symptoms who was hospitalized June 10, 2026; NiV causes severe encephalitis with high case fatality rates.

LISTERIA - U.S. PREPARED MEALS (ONGOING)

  • As of October 30, 2026, CDC is urging consumers to check refrigerators and freezers for recalled prepared meal products as illnesses continue to be reported despite recalls; a September 26 update added 3 more illnesses and 1 additional death to the outbreak.
  • A separate November 7, 2026 recall flagged Fresh to You Sausage, Egg and Cheese Biscuit Sandwiches by Fresh and Ready Foods LLC of Renton, Washington as potentially contaminated with Listeria monocytogenes.

DRUG-RESISTANT BACTERIA ON THE RISE

  • A CDC report published September 23, 2026 found a dramatic increase in a dangerous type of drug-resistant bacteria in the United States, adding urgency to the ongoing antimicrobial resistance threat.

SALMONELLA - MULTIPLE U.S. VECTORS STILL ACTIVE

  • CDC is tracking a Salmonella outbreak linked to raw oysters spanning 22 states with 64 cases as of an October 20 outbreak page update.
  • An October 30 recall flagged potential Salmonella contamination in one lot of 365 Whole Foods Market Ashwagandha Capsules (lot 2025-26227) made by Vitality Works Inc. of Albuquerque, New Mexico.

E. COLI - RAW MILK CHEESE

  • An ongoing CDC outbreak investigation links E. coli to raw milk cheese, with a food safety alert specifically naming Family Farmstead Dairy of Worcester, New York, which is recalling a lot of raw mild cheddar cheese potentially contaminated with E. coli O157:H7 as of October 15, 2026.

FOOD SAFETY ALERTS THIS WEEK

  • HAIFA SMOKED FISH of Queens, New York, recalled approximately 560 lbs of Cold Smoked Sprats on October 27, 2026 due to potential Clostridium botulinum contamination; the bacterium can cause life-threatening illness.
  • Snack Right Super Foods (Brad's Raw Chips) of Coral Gables, Florida, recalled Brad's Plant Based Crunchy Kale (2 oz) and Brad's Veggie Chips Kale (3 oz) on November 2, 2026 due to potential thallium contamination, a toxic heavy metal.
  • SLR Food Distribution of Hicksville, New York, recalled Wise Wife Brand Ground Cinnamon on October 29, 2026 for elevated lead levels.
  • FSIS issued a November 6, 2026 public health alert for frozen not-ready-to-eat meat and poultry products due to misbranding and undeclared allergens.

🧬 LONGEVITY & AGING

GDF11 AND MUSCLE AGING

  • A study published in Genes and Disease (February 2026, Europe PMC) found that GDF11, a circulating protein in blood, restores the function of skeletal muscle satellite cells — the stem cells responsible for muscle repair — by activating the MYC transcription factor, offering a mechanistic pathway to treat sarcopenia, the age-related loss of muscle mass that drives frailty.

AI READS YOUR FACE FOR BIOLOGICAL AGE

  • A model development and validation study in Lancet Digital Health (FAHR-Face) by Haugg et al., including authors from institutions such as Brigham and Women's Hospital and the Broad Institute area, demonstrated that a foundation AI model can estimate biological age and health status from face photographs with meaningful prognostic accuracy, potentially enabling low-cost aging biomarker screening.

AI OUTPERFORMS CLINICIANS IN CARDIAC MORTALITY PREDICTION

  • A retrospective multicentre study in Lancet Digital Health by Joy et al. found that AI-based left-ventricular segmentation of cardiac MRI outperformed clinician-performed segmentation for predicting all-cause mortality, suggesting AI cardiac imaging could sharpen longevity risk stratification.

STATIN DISCONTINUATION IN OLDER FRAIL PATIENTS

  • A large population-wide retrospective cohort study in England using Clinical Practice Research Datalink data, published in Lancet Healthy Longevity by Seeley et al., examined the efficacy and safety of stopping statin therapy in patients 65 years and older, stratified by frailty status — findings that could meaningfully reshape deprescribing decisions for a drug taken by millions of older adults.

ANIMAL PROTEIN AND DEMENTIA - GLOBAL ANALYSIS

  • A global ecological analysis published in Future Science OA (November 2, 2026) by You et al. found associations between animal protein supply, cognitive aging trajectories, and female-to-male dementia disparities across countries, adding dietary protein to the geroscience conversation around sex-specific dementia risk.

SENESCENCE-MIMETIC CANCER IMMUNOTHERAPY

  • Researchers published in Biomaterials (October 2026) a hybrid nanovesicle artificial antigen-presenting cell that integrates endogenous tumor antigen display with senescence-mimetic erythrocyte membrane signals to prime T cells in the spleen — a novel approach that co-opts senescence biology for anti-tumor immunity.

OSTEOARTHRITIS REGENERATION - NANOZYME HYDROGEL

  • A study in Bioactive Materials (October 2026) by Yu et al. described a DNA-adsorbing nanozyme hydrogel that reprograms the inflammatory and oxidative microenvironment of arthritic joints to support stem cell-based cartilage repair, addressing a key barrier in treating osteoarthritis in aging populations.

OLDER ADULTS IN HUMANITARIAN CRISES - OVERLOOKED POPULATION

  • A cluster of Lancet Healthy Longevity papers (van Boetzelaer, Falb, Escobio, Karunakara et al.) collectively argues that older adults are systematically overlooked in humanitarian emergencies, lacking access to palliative care, reproductive health services, malnutrition programs, and person-centred frameworks — calling for a rights-based PARTICIPATE framework to close this gap.

💊 NEW CURES & APPROVALS

ORGOVYX SUPPLEMENTAL APPROVAL - PROSTATE CANCER / ENDOMETRIOSIS

  • Sumitomo Pharma America received a supplemental approval (SUPPL AP) for ORGOVYX (relugolix), an oral GnRH receptor antagonist, under NDA214621; relugolix is already indicated for advanced prostate cancer and uterine fibroids, and the supplement expands its approved profile.

ZYNLONTA SUPPLEMENTAL APPROVAL - BLOOD CANCER

  • ADC Therapeutics SA received a supplemental approval for ZYNLONTA (loncastuximab tesirine-lpyl), an antibody-drug conjugate targeting CD19, under BLA761196; it is indicated for relapsed or refractory large B-cell lymphoma in adults.

RELEUKO SUPPLEMENTAL APPROVAL - NEUTROPENIA

  • Kashiv Biosciences LLC received a supplemental approval for RELEUKO (filgrastim-ayow), a granulocyte colony-stimulating factor biosimilar, under BLA761082, used to reduce infection risk from severe neutropenia in chemotherapy patients.

HYDROXYUREA ORIGINAL APPROVAL - ESJAY PHARMA

  • Esjay Pharma received an original approval (ORIG AP) for hydroxyurea under ANDA220300; hydroxyurea is used in sickle cell disease, certain leukemias, and other conditions, expanding generic availability.

FLUTICASONE PROPIONATE INHALER - TEVA

  • Teva Pharmaceuticals USA received an original approval for a fluticasone propionate inhaled formulation under ANDA209917, adding a new generic corticosteroid option for asthma and COPD.

EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE - MACLEODS

  • Macleods Pharmaceuticals received a supplemental approval for the emtricitabine and tenofovir disoproxil fumarate combination under ANDA203442, a key antiretroviral combination used in HIV treatment and PrEP.

🧪 CLINICAL TRIALS

40 HZ AUDIO-VISUAL STIMULATION FOR ALZHEIMER'S DISEASE

  • A new double-blind randomized controlled trial (NCT07926438) registered November 9, 2026, at the First Affiliated Hospital of Xiamen University will enroll 50 participants aged 50 to 80 with Alzheimer's-derived mild cognitive impairment or mild AD to test 40 Hz audio-visual sensory stimulation therapy — a gamma-frequency entrainment approach shown preclinically to reduce amyloid and tau pathology.

PACRITINIB IN MYELODYSPLASTIC SYNDROMES

  • Trial NCT06303193 is evaluating pacritinib, a kinase inhibitor targeting CSF1R, IRAK1, JAK2, and FLT3, in adults and pediatric patients 12 and older with myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms — diseases strongly associated with aging that can progress to acute myeloid leukemia.

MARSTACIMAB FOR HEMOPHILIA A AND B

  • An open-label multicenter study (NCT07923981) registered November 9, 2026, will enroll approximately 95 adolescents and adults aged 12 to under 75 with mild to moderate hemophilia A or B without inhibitors but with a severe bleeding phenotype to evaluate marstacimab prophylaxis efficacy and safety.

NAVEPEGRITIDE PLUS LONAPEGSOMATROPIN FOR ACHONDROPLASIA

  • A Phase 3 pivotal trial (NCT07924059) registered November 9, 2026, will evaluate dual subcutaneous weekly therapy with navepegritide and lonapegsomatropin in children aged 2 to 17 years with achondroplasia (ACH), targeting the growth hormone and C-natriuretic peptide pathways simultaneously.

ZOTIRACICLIB FOR IDH-MUTANT MALIGNANT GLIOMA

  • Trial NCT05588141 (Protocol 000860) is a Phase I/II study assessing zotiraciclib in patients with recurrent malignant gliomas carrying IDH1 or IDH2 mutations — a population with limited options and an aggressive disease course.

CROVALIMAB FOR PNH

  • Study NCT04654468 is enrolling approximately 50 participants aged 12 or older weighing at least 40 kg with paroxysmal nocturnal hemoglobinuria (PNH) who are complement-inhibitor naive to receive crovalimab, a novel recycling anti-C5 antibody, for at least 24 weeks.

ULTRA-PROCESSED DIET AND BRAIN DOPAMINE

  • A registered trial (NCT07920952) at an NIH-affiliated center will use neuroimaging to test how ad libitum ultra-processed versus unprocessed diets affect dopamine levels in healthy people's brains, aiming to quantify neurobiological reward-pathway mechanisms behind dietary choices relevant to metabolic aging.

📢 PUBLIC HEALTH

HEPATITIS B VACCINE POLICY SHIFT - INFANTS

  • Effective December 16, 2025, CDC adopted individual-based decision-making for hepatitis B immunization for infants born to mothers who test negative for hepatitis B virus, following an ACIP vote in December 2025 that departed from universal birth-dose recommendations for this sub-population.

CHILDHOOD IMMUNIZATION SCHEDULE UPDATE

  • On January 4, 2026, Acting CDC Director Jim O'Neill signed a decision memorandum acting on a Presidential Memorandum to update the childhood immunization schedule; COVID-19 vaccination guidance was moved to individual-based decision-making, and standalone varicella vaccination for toddlers was adopted.

RABIES ACTIVITY UP

  • CDC issued a statement on September 10, 2026 noting increases in animal rabies activity and associated human exposures, urging people to avoid contact with wildlife and to seek post-exposure prophylaxis promptly if bitten.

CONGENITAL SYPHILIS RISES FOR 12TH STRAIGHT YEAR

  • CDC data released September 24, 2025 showed U.S. congenital syphilis cases rose for the 12th consecutive year in 2024, underscoring persistent gaps in prenatal screening and treatment.

DRUG OVERDOSE DEATHS CONTINUE HISTORIC DECLINE

  • Provisional 2024 CDC data confirmed a 27 percent decrease in drug overdose deaths compared to the prior year, following a nearly 24 percent decline reported earlier; CDC launched a new Overdose Prevention Data Channel on August 31, 2026 to track trends in real time.

BIOSURVEILLANCE MILESTONE

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, strengthening the ability to detect emerging pathogens at the border.

This briefing is informational only and does not constitute medical advice. Consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  9. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  10. Shamonda virus in human - France — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261110-02-v132 · 2026-11-10 02:01 UTC · pulse.uzylab.com